Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Dana-Farber Cancer Institute · Harvard University · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
518
total citations
- FWCI
- 19.59
- Percentile
- 100%
- References
- 26
Citations per year
Authors
9- IEIan E. KropCorresponding
Dana-Farber Cancer Institute, Harvard University
- SKSung‐Bae Kim
University of Ulsan, Ulsan College, Asan Medical Center
- AGAntonio González-Martı́n
MD Anderson Cancer Center Madrid
- PLPatricia LoRusso
University Medical Center, Yale University, Yale Cancer Center
- JFJean-Marc Ferrero
Centre Antoine Lacassagne
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab emtansine
- Lapatinib
- Internal medicine
- Trastuzumab
- Oncology
- Breast cancer
- Interim analysis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.